| Literature DB >> 35096862 |
Simin Li1, Wanchen Ning1, Wei Wang1, Dirk Ziebolz2, Aneesha Acharya3, Gerhard Schmalz2, Jianjiang Zhao4, Shaohong Huang1, Hui Xiao1.
Abstract
Background: This systematic review evaluates the oral health-related quality of life (OHRQoL) of patients with chronic respiratory diseases.Entities:
Keywords: COPD; lung; oral health; oral health-related quality of life; respiratory disease
Year: 2022 PMID: 35096862 PMCID: PMC8790480 DOI: 10.3389/fmed.2021.757739
Source DB: PubMed Journal: Front Med (Lausanne) ISSN: 2296-858X
Figure 1The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) diagram for the systematic review process in this study (17).
Overview of the included studies.
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|
| Saltness et al. ( | COPD | Norway | 100 | Monocentric cross-sectional study | 65.9 ± 10.1 | 39% | 56% | No |
| Patrick et al. ( | Cystic fibrosis | USA | 39 | Multicentric cross-sectional | 43.6% 8–12 | n/a | 53% | No |
| Schmalz et al. ( | Lung transplantation | Germany | 60 | Monocentric cross-sectional study | 54.03 ± 9.97 | 0% | 50% | Yes: |
| Gaeckle et al. ( | COPD | USA | 20 | Monocentric prospective observational study (follow-up: 60 days) | 60 (56–68) | 50% | 60% | Yes: |
| Grillo et al. ( | Sleep-disordered breathing | Italy | 61 | Monocentric cross-sectional study | 12.4 ± 3.1 | 16.4% | 54.1% | Yes: |
| Tamsas et al. ( | Obstructive sleep apnoea | USA | 31 | Monocentric cross-sectional study | 12.8 ± 3.1 | 14% | 52% | Yes: |
| Brasil-Oliveira et al. ( | Severe asthma | Brazil | 40 | Monocentric cross-sectional study | 51.8 ± 10.8 | 0% | 15% | Yes: |
Values are presented as the mean values ± SD, mean values (range), or percentages.
OHRQoL, oral health-related quality of life; n/a, not applicable; COPD, chronic obstructive pulmonary disease.
Quality assessment of the included studies according to the Agency for Healthcare Research and Quality (ARHQ) (18).
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|
| (1) Define the source of information (survey, record review) | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| (2) List inclusion and exclusion criteria for exposed and unexposed subjects (cases and controls) or refer to previous publications | Yes | No | Yes | Yes | Yes | Yes | Yes |
| (3) Indicate time period used for identifying patients | Yes | No | Yes | Yes | Yes | No | Yes |
| (4) Indicate whether or not subjects were consecutive if not population-based | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| (5) Indicate if evaluators of subjective components of study were masked to other aspects of the status of the participants | No | No | No | No | No | No | No |
| (6) Describe any assessments undertaken for quality assurance purposes (e.g., test/retest of primary outcome measurements) | Yes | NA | Yes | Yes | Yes | NA | Yes |
| (7) Explain any patient exclusions from analysis | Yes | NA | NA | Yes | Yes | NA | NA |
| (8) Describe how confounding was assessed and/or controlled. | Yes | Yes | U | Yes | Yes | Yes | Yes |
| (9) If applicable, explain how missing data were handled in the analysis | NA | Yes | NA | NA | NA | NA | NA |
| (10) Summarize patient response rates and completeness of data collection | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| (11) Clarify what follow-up, if any, was expected and the percentage of patients for which incomplete data or follow-up was obtained | NA | NA | NA | Yes | NA | NA | NA |
| Total score | 8 | 5 | 6 | 9 | 8 | 5 | 7 |
Oral health parameters and respective main results if they presented as the mean values ± SD, means (range), or percentages in the included studies.
|
|
|
|
|
|
|
|---|---|---|---|---|---|
| Saltness et al. ( | 44% <20 teeth | n/a | n/a | n/a | 9% hyposalivation, 39% oral health problems |
| Patrick et al. ( | n/a | n/a | n/a | n/a | n/a |
| Schmalz et al. ( | M-T: 8.17 ± 5.82 | DMF-T: 20.53 ± 5.09, D-T: 0.82 ± 1.85, F-T 11.55 ± 4.57 | n/a | 98% moderate to severe periodontitis | n/a |
| Gaeckle et al. ( | Number of teeth: 16.5 (8.5–23.5) | n/a | PI: 2.2 (1.5–2.8) | n/a | n/a |
| Grillo et al. ( | n/a | DMFS: 13.6 ± 4.7, dmfs: 8.5 ± 2.3 | n/a | PPD: 2.4 ± 0.5, BOP: 0.9 ± 0.2 | n/a |
| Tamsas et al. ( | n/a | dmfs: 5.1 ± 8.5, DMFS: 15.2 ± 11.8 | n/a | BOP: 87%, PPD mean 2.7 ± 1.3 | Comprehensive information on oropharyngeal morphology reported |
| Brasil-Oliveira et al. ( | M-T: 7.9 ± 7.2, | D-T: 1.4 ± 2.0, F-T: 4.2 ± 3.7, DMF-T: 13.5 ± 6.5 | n/a | Periodontitis: 92.5% | Reduced salivary flow: 80% |
M-T, missing teeth; D-T, decayed teeth; F-T, filled teeth; DMF-T, decayed-, missing-, and filled teeth index; PI, plaque index; GI, gingival index; PPD, periodontal probing depth; n/a, not applicable;
inclusion criterion: at least 6 remaining teeth.
Figure 2The Oral Health Impact Profile (OHIP) values of included studies on adults and values for healthy controls, if applicable.
Figure 3The Child OHIP (COHIP) values for children in included studies and of healthy controls, if applicable.
Applied assessments for OHRQoL and relevant results for the included studies.
|
|
|
|
|
|
|
|---|---|---|---|---|---|
| Saltness et al. ( | OHIP 14: 5.2 ± 7.7 | n/a | Higher OHIP 14 related to worse MCS SF-36 | Oral health problems related to poorer OHRQoL | n/a |
| Patrick et al. ( | COHIP: A: 57.0 ± 10.0, B: 67.5 ± 14.2 | n/a | n/a | n/a | Number of medications correlated with better COHIP |
| Schmalz et al. ( | OHIP 14: 1.70 ± 2.70 | No, OHIP 14: 1.54 ± 2.86 | n/a | No associations detected | No |
| Gaeckle et al. ( | OHIP 14: 12 (6–18.5) | Yes, OHIP 14: 4.5 (0–8) | n/a | n/a | No |
| Grillo et al. ( | COHIP: 23.2 ± 4.6 | Yes, COHIP: 15.9 ± 3.8 | n/a | Malocclusion | Mallampati class and Obesity correlated with worse COHIP |
| Tamsas et al. ( | COHIP: 29.7 ± 15.2 | Yes, COHIP: 11.8 ± 10.2 | n/a | n/a | n/a |
| Brasil-Oliveira et al. ( | OHIP 14: 11.0 ± 10.5 (mild-to-moderate asthma: 6.2 ± 7.4) | Yes, OHIP 14: 1.4 ± 2.6 | Higher OHIP 14 correlation with better PCS and MCS of SF-36 | n/a | n/a |
OHRQoL, oral health-related quality of life; n/a, not applicable; OHIP, Oral Health Impact Profile; COHIP, Child OHIP; PCS, physical compound summary; MCS, mental compound summary; SF-36, Short Form 36 Health Survey Questionnaire.
Subscales of OHRQoL in the included studies, if applicable.
|
| |||||||
|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
| Brasil-Oliveira et al. ( | 1.2 ± 2.0 | 3.0 ± 2.4 | 1.8 ± 2.5 | 2.1 ± 2.3 | 2.6 ± 2.3 | 1.1 ± 0.8 | 0.6 ± 1.6 |
|
| |||||||
|
|
|
|
|
|
|
| |
| Patrick et al. ( | A: 19.3 ± 4.3, B: 21.9 ± 6.4 | A: 7.7 ± 1.4, B: 8.2 ± 3.2 | A: 10.1 ± 3.1, B: 13.4 ± 5.2 | A: 4.5 ± 0.9, B: 4.9 ± 2.2 | A: 12.3 ± 3.9, B: 14.8 ± 2.8 | A: 3.8 ± 1.6, B: 4.6 ± 1.4 | |
| Tamasas et al. ( | 14.1 ± 5.5 | 3.7 ± 3.0 | 3.5 ± 5.6 | 1.0 ± 1.7 | 7.3 ± 5.5 | n/a | |
The results are given as the mean values ± SD or otherwise as percentages. OHIP, Oral Health Impact Profile.
significant different from control.
Group A: 8–12 years (n = 17); group B: 13–17 years (n = 22).